Security Snapshot

SPDR SERIES TRUST - BLOOMBERG EMERGI (EBND) Institutional Ownership

CUSIP: 78464A391

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

212

Shares (Excl. Options)

90,920,788

Price

$21.37

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / BLOOMBERG EMERGI
Symbol
EBND
Price per share
$20.64
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
90,920,788
Total reported value
$1,942,973,780
% of total 13F portfolios
0%
Share change
+3,625,054
Value change
+$77,470,913
Number of holders
212
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • EBND - SPDR SERIES TRUST - BLOOMBERG EMERGI is tracked under CUSIP 78464A391.
  • 212 institutions reported positions in Q4 2025.
  • Schedule 13D/13G significant owner rows are not currently available.

What Changed

  • Holder count moved from 212 to 38 between Q4 2025 and Q1 2026.
  • Reported value moved from $1,942,973,780 to $31,949,265.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 212 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 78464A391?
CUSIP 78464A391 identifies EBND - SPDR SERIES TRUST - BLOOMBERG EMERGI in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

As of 31 Dec 2025, 212 institutional investors reported holding 90,920,788 shares of SPDR SERIES TRUST - BLOOMBERG EMERGI (EBND).

Institutional Holders of SPDR SERIES TRUST - BLOOMBERG EMERGI (EBND) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,535,064 $31,949,265 -$5,158,395 $20.64 38
2025 Q4 90,920,788 $1,942,973,780 +$77,470,913 $21.37 212
2025 Q3 86,734,737 $1,852,645,595 +$88,186,421 $21.36 200
2025 Q2 82,545,312 $1,766,400,891 +$63,229,130 $21.40 180
2025 Q1 79,420,829 $1,593,985,193 -$46,009,769 $20.07 188
2024 Q4 81,764,184 $1,596,876,154 -$68,425,759 $19.53 208
2024 Q3 84,961,104 $1,806,805,483 -$10,388,328 $21.27 191
2024 Q2 85,546,416 $1,701,521,593 -$61,805,862 $19.89 182
2024 Q1 87,000,727 $1,783,500,412 +$112,814,937 $20.50 191
2023 Q4 81,495,442 $1,730,868,624 -$5,032,081 $21.24 185
2023 Q3 81,648,415 $1,618,577,567 +$180,509,751 $19.83 164
2023 Q2 72,188,043 $1,527,574,844 -$10,659,796 $21.16 174
2023 Q1 72,624,178 $1,540,733,194 -$478,073,000 $21.22 174
2022 Q4 94,848,026 $1,952,773,101 -$21,617,006 $20.56 167
2022 Q3 95,624,177 $1,814,399,136 +$1,520,194 $18.97 119
2022 Q2 95,269,580 $1,947,163,782 +$1,087,225,498 $20.45 123
2022 Q1 42,353,489 $962,711,034 +$76,016,656 $22.73 123
2021 Q4 38,827,787 $948,903,675 -$228,299,813 $24.44 130
2021 Q3 48,091,544 $1,216,294,783 +$108,358,486 $25.30 127
2021 Q2 43,793,629 $1,156,738,538 +$129,596,327 $26.43 128
2021 Q1 38,826,891 $1,011,152,151 +$259,112,243 $26.02 127
2020 Q4 28,887,952 $807,008,209 +$17,465,055 $28.05 110
2020 Q3 27,769,911 $729,997,938 +$146,898,338 $26.28 102
2020 Q2 22,567,400 $592,107,387 -$213,708,840 $26.21 102
2020 Q1 30,560,336 $748,979,085 -$27,367,239 $24.49 97
2019 Q4 31,599,477 $881,907,275 +$143,527,724 $27.91 98
2019 Q3 26,316,233 $716,236,528 +$45,144,783 $27.21 86
2019 Q2 24,552,329 $683,114,016 +$59,300,544 $27.82 74
2019 Q1 22,430,480 $603,652,513 +$80,547,739 $26.91 73
2018 Q4 19,426,159 $515,475,004 +$40,069,586 $26.52 67
2018 Q3 17,806,482 $468,672,648 +$38,700,667 $26.31 59
2018 Q2 16,322,432 $440,185,290 -$140,725,096 $26.96 61
2018 Q1 21,429,272 $650,799,773 +$261,039,208 $30.38 64
2017 Q4 12,834,665 $381,114,865 +$243,662,072 $29.68 56
2017 Q3 4,601,331 $137,269,040 +$40,824,285 $29.88 41
2017 Q2 3,217,353 $93,339,672 -$3,328,139 $29.04 40
2017 Q1 3,398,940 $95,840,281 +$4,812,071 $28.19 37
2016 Q4 3,252,411 $86,540,760 -$37,628,360 $26.58 41
2016 Q3 4,644,430 $131,567,424 -$19,744,169 $28.33 50
2016 Q2 5,202,192 $144,880,383 +$129,703,844 $27.85 48
2016 Q1 638,193 $17,211,446 -$2,377,514 $26.97 25
2015 Q4 797,840 $19,681,942 -$14,981,129 $24.59 30
2015 Q3 1,340,349 $33,015,000 -$1,422,136 $24.58 34
2015 Q2 1,502,237 $40,679,000 +$1,492,951 $27.08 36
2015 Q1 1,446,984 $39,431,000 -$4,429,201 $27.25 32
2014 Q4 1,597,635 $45,414,000 +$2,266,048 $28.41 35
2014 Q3 1,497,354 $44,340,000 +$14,371,293 $29.61 38
2014 Q2 984,456 $30,731,000 -$13,058,059 $31.22 35
2014 Q1 1,411,643 $41,888,000 -$75,262,199 $29.65 41